**HIMSS 2021 Cancer Section Data Values**

|  |  |  |
| --- | --- | --- |
| DEMOGRAPHICS |  |  |
| Age: | < > | Optimal with mid 50-75; Align with the Use Case |
| CANCER |  |  |
| Diagnosis Date | < > | Align with the Use Case |
| Histology | 80703    Squamous Cell Carcinoma |  |
| Clinical Grade | 3 Poorly differentiated |  |
| Pathologic Grade | < > | TBD: Complete if surgery is performed |
| Clinical Grade Post Therapy | < > | TBD: Complete if chemo is given before surgery is performed |
| Pathologic Grade Post Therapy | < > | TBD: Complete if chemo is given before surgery is performed |
| Primary Site: | C34.1     Upper lobe of Lung |  |
| Laterality | 1             Right |  |
| AJCC TNM Edition | 8th |  |
| Clinical Stage Group | IIIA |  |
| cT | T1b |  |
| cN | N2 |  |
| cM | M0 |  |
| Pathologic Stage Group | < > | TBD: Complete if surgery is performed |
| pT | < > | TBD: Complete if surgery is performed |
| pN | < > | TBD: Complete if surgery is performed |
| pM | < > | TBD: Complete if surgery is performed |
| TREATMENT |  |  |
| Chemotherapy option 1 | Docetaxel (30mg/m2)and carboplatin |  |
| Chemotherapy option 2 | Pacitaxel (110mg/m2)and carboplatin |  |
| Chemotherapy option 3 | Docetaxel plus gemcitabin |  |
|  |  |  |
| ADD: Immunotherapy | Osimertinib (Tagrisso) | For biopsy with a **positive** EGFR Tumor Marker |
| ADD: Immunotherapy | pembrolizumab (Keytruda) | If patient is not a candidate for Surgery |
| Radiation | < > | TBD |
| Surgery | < > | TBD |